Psoriasis vulgaris treated successfully with mycophenolate mofetil

British Journal of Dermatology

Volumn 138, Issue 1, 1998, Pages 179-181

  Haufs, M G ^a   Beissert, S ^a   Grabbe, S ^a   Schutte B ^a   Luger, T A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; ETRETIN; GUANINE NUCLEOTIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AGED; ARTICLE; CASE REPORT; DNA SYNTHESIS; DRUG EFFICACY; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; NUCLEOTIDE METABOLISM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; RNA SYNTHESIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; PSORIASIS;

EID: 0031910537     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02048.x     Document Type: Article

References (19)

1. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996; 110: 199-206.
2. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1: 442-7.
3. Ramirez-Bosca A, Martinez-Ojeda L, Valcuende-Cavero F, Castells-Rodellas A. A study of local immunity in psoriasis. Br J Dermatol 1988; 119: 587-95.
4. Kapp A. Elevated levels of soluble CD8 antigen in sera of patients with psoriasis - a possible sign of suppressor/cytotoxic T-cell activation. Arch Dermatol Res 1990; 282: 6-7.
5. Bos JD, Hagenaars C, Das PK et al. Predominance of memory T cells (CD4+, CDw29+) over naive T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-50.
6. Turbitt ML, Akhurst RJ, White SI, MacKie RM. Localization of elevated transforming growth factor-alpha in psoriatic epidermis. J Invest Dermatol 1990; 95: 229-32.
7. Greaves MW. Neutrophil polymorphonuclears, mediators and the pathogenesis of psoriasis. Br J Dermatol 1985; 109: 115-8.
8. Schön MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nature Med 1997; 3: 183-8.
9. Pichlmayr R, European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-5.
10. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolatmofetil. Springer Semin Immunopathol 1993; 14: 353-69.
11. Young CJ, Sollinger HW, RS-61443: a new immunosuppressive agent. Transplant Proc 1994; 26: 3144-50.
12. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28.
13. van der Woude FJ. Mycophenolate mofetil (RS-61443): nothing new under the sun or an important break-through in the field of transplantation? Nephrol Dialysis Transplant 1995; 10: 1112-15.
14. Allison AC, Eugui EM. Mycophenolatc mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7: 96-112.
15. Böhm M, Beissert S, Schwarz T et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349: 541.
16. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. J Am Acad Dermatol 1987; 17: 962-71.
17. Marinari R; Fleischmajer R, Schragger AH, Rosenthal AL. Mycophenolic acid in the treatment of psoriasis. Arch Dermatol 1977; 113: 930-2.
18. Jones EL, Epinette WW, Hackney VC et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537-42.
19. Lee WA, Gu L, Mikszal AR et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161-3.